Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 28/02/2025

    Scientists discover the function of a mysterious HIV component

    A research team including scientists from Heidelberg University Hospital has gained new insights into HIV-1. Researchers have discovered the mechanism behind an important step in the life cycle of HIV. Working together with teams at Heidelberg and Yale Universities, they found that the enigmatic “spacer peptide 2”, one of the virus components, plays a key role in converting immature HIV-1 particles into infectious particles.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/scientists-discover-function-mysterious-hiv-component
  • Press release - 27/02/2025

    EU Project: New Molecular Interventions against Virus Infections

    Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication. Scientists work on new approaches to combating highly dangerous viral diseases such as yellow fever or Lassa fever. The European Union is supporting the project over a period of five years to the tune of just under eight million euros.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-project-new-molecular-interventions-against-virus-infections
  • Press release - 10/02/2025

    Medical textiles with infection protection

    In collaboration with Heraeus, the German Institutes of Textile and Fiber Research (DITF) are developing fibers and textiles with a novel infection protection system. The basis is an antimicrobial mechanism of action licensed from Heraeus and marketed under the name AGXX. The goal of the collaboration is to optimally integrate the AGXX technology into textile finishes and coatings and to incorporate it into fiber-spinnable polymers.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/medical-textiles-infection-protection
  • Project REVeyeVE - 06/02/2025 Es ist eine einzelne gedrehte, helle Struktur vor schwarzem Hintergrund zu sehen.

    Targeted, virus-free gene therapy for the eye using degradable nanopropellers

    Eye diseases that result in blindness in young people are primarily caused by genetic mutations. An interdisciplinary team of researchers from the Universities of Tübingen and Heidelberg is developing an innovative gene therapy method using biodegradable, magnetic nanopropellers. These innovative nanopropellers can effectively deliver intact genes into the affected cells, offering a potential solution for treating genetic disorders of this kind.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Targeted-virus-free-gene-therapy-for-the-eye-using-degradable-nanopropellers
  • Press release - 23/01/2025

    How the Ebola virus replicates in cells

    Like all viruses, the Ebola virus is dependent on host cells in order to replicate. Researchers at Heidelberg University Hospital, in collaboration with colleagues from the Friedrich Loeffler Institute, have been able to show for the first time using state-of-the-art imaging techniques how the replication compartments of the Ebola virus change during replication in infected cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-ebola-virus-replicates-cells
  • Press release - 16/01/2025

    New weapons against viruses

    Dr. Petr Chlanda, virologist and research group leader at the Heidelberg Medical Faculty of Heidelberg University, has been awarded more than 720,000 euros in funding from the European Union for his research into new therapies against viruses. His work is part of the interdisciplinary, international DEFENDER project, which is developing innovative approaches to combat emerging and re-emerging viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-weapons-against-viruses
  • Press release - 07/01/2025

    Researchers have a better understanding of how our cells dispose of waste while developing ways to control it

    A research team from Freiburg and Frankfurt has discovered how cells recognise and internally break down waste. The results are relevant for the development of therapies for diseases such as Alzheimer’s.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-have-better-understanding-how-our-cells-dispose-waste-while-developing-ways-control-it
  • Press release - 09/12/2024

    Brain tumour cells rapidly integrate into brain-wide neuronal circuits

    Researchers at the Medical Faculty of Heidelberg University and the Heidelberg University Hospital have used modified rabies viruses to label glioblastoma tumour cells and their direct cell contacts in the mouse brain. The new method showed that the tumour cells are connected to different types of nerve cells throughout the entire brain at a very early stage of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-tumour-cells-rapidly-integrate-brain-wide-neuronal-circuits
  • Press release - 05/11/2024

    Heidelberg scientist receives highly endowed EC synergy grant

    Heidelberg scientist Dr Venera Weinhardt has received an ERC Synergy Grant for a pioneering biomedical research project. The European Research Council (ERC) is granting this funding to advance soft X-ray microscopy. This imaging technique along with other innovations will be used to investigate the hepatitis E virus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-scientist-receives-highly-endowed-ec-synergy-grant
  • Press release - 05/07/2024

    Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy

    The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy
  • Press release - 31/05/2024

    Heidelberg University successful with six bids for collaborative research

    In the current approval round of the German Research Foundation (DFG) Heidelberg University has been successful with six applications for grants to fund major, internationally visible research consortia. The six research consortia − three of them will reach the maximum funding length of twelve years after their extension − are to receive financial resources totalling nearly 87 million euros over a period of four years.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-university-successful-six-bids-collaborative-research
  • Press release - 24/04/2024

    CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

    Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1) virus, considered to be potential future pandemic threat. Study will assess monovalent vaccine candidate, encoding an influenza A H5-antigen using proprietary second-generation mRNA backbone.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-start-combined-phase-12-study-avian-influenza-h5n1-development-collaboration-gsk
  • Press release - 10/04/2024

    Growth through medical technology: Bosch and Randox invest heavily in the Vivalytic analysis platform

    With its Vivalytic analysis platform, Bosch has set itself the goal of making fast and highly precise diagnostics accessible at the point of care – and aims to use molecular diagnostics to become a leading provider in the market by 2030. To achieve this, Bosch has now agreed on a strategic partnership with Randox Laboratories Ltd., a leading diagnostic and medical technology company.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/growth-through-medical-technology-bosch-and-randox-invest-heavily-vivalytic-analysis-platform
  • Press release - 13/03/2024

    Protection from an unexpected source

    Contrary to common belief, not all viruses are harmful to their hosts. Sometimes viruses can even protect their hosts from infection by other viruses. Scientists at the Max-Planck-Institute for Medical Research in Heidelberg and their collaborators have now demonstrated that this is the case for so-called endogenous virophages: small DNA viruses that are mostly found inserted into the genomes of single-cell eukaryotes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/protection-unexpected-source
  • Press release - 04/01/2024

    Key player in viral heart inflammation discovered

    Inflammation of the heart muscle, also known as myocarditis, is a serious consequence of a viral infection. This can impede the heart’s ability to pump blood in the long term. In a current study, researchers of the Faculty of Medicine of the University of Freiburg have discovered a new approach for treating myocarditis.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/key-player-viral-heart-inflammation-discovered
  • Press release - 29/11/2023

    EU funds research into causes and new therapies for multiple sclerosis

    The progression of multiple sclerosis (MS) can usually be slowed down with medication, but a cure is currently not possible. It is now established that Epstein-Barr viruses are involved in the development of MS. However, it is not known how the pathogens trigger the disease. The European Union is now funding the international research consortium BEHIND-MS as part of its HORIZON Europe program.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eu-foerdert-forschung-zu-ursachen-und-neuen-therapien-der-multiplen-sklerose
  • Press release - 18/10/2023

    SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease

    Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen
  • Press release - 22/05/2023

    Prevention of pandemics

    Volkswagen Foundation to fund international research project with around 1.5 million euros. Interdisciplinary team led by the Institute for Global Health at Heidelberg University Hospital to research the transmission of pathogens from animals to humans in Thailand and Laos. Long-term goal is to develop sustainable preventive measures against future pandemics.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/prevention-pandemics
  • Press release - 08/05/2023

    CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

    Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates. Candidates developed in collaboration with GSK within broad infectious disease vaccine program encode for antigens covering four WHO-recommended flu strains.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-dosing-first-participant-combined-phase-12-study-multivalent-modified-influenza-vaccine-candidates-developed-c
  • Press release - 23/03/2023

    Targeted computer modelling to accelerate antiviral drug development

    Effective drugs against viral diseases like COVID-19 are urgently needed now and in the future. The emergence of viral mutants and yet unknown viruses could push vaccines to their limits. The DZIF scientist and bioinformatician Andreas Dräger from the University of Tübingen is working on a computer-based method that can help to accelerate the time-consuming identification and development of antiviral agents. Using a novel analysis technique that…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/computermodellierung-zur-schnelleren-entwicklung-antiviraler-medikamente
  • Immune complexes in COVID-19 - 01/03/2023 Zu sehen ist in einem Schema, wie einzelne Faktoren zu einer schweren Corona-Erkrankung führen können.

    Vicious circle of hyperinflammation

    Whether a person experiences only a mild malaise or a critical course of disease after a coronavirus infection apparently depends on the antigen-antibody complexes that form in our body. The discovery of these immune complexes set a group of researchers, headed up by Prof. Dr. Hartmut Hengel from the Freiburg University Medical Centre, on the trail of a vicious circle of constantly escalating inflammation.

    https://www.gesundheitsindustrie-bw.de/en/article/news/vicious-circle-hyperinflammation
  • Press release - 06/01/2023

    CureVac Announces Positive Data on Joint COVID-19 and Flu mRNA Vaccine Development Programs

    CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology. The tested vaccine candidates are being developed in collaboration with GSK.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-announces-positive-data-joint-covid-19-and-flu-mrna-vaccine-development-programs
  • Press release - 24/11/2022

    SARS-CoV-2 detection in 30 minutes using gene scissors

    Researchers of the University of Freiburg introduce biosensor for the nucleic acid amplification-free detection of SARS-CoV-2 RNA.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-nachweis-30-minuten-mit-der-genschere
  • Press release - 17/11/2022

    MEDICA and COMPAMED present themselves as extremely vital platforms in turbulent times

    MEDICA and COMPAMED continue to develop in an extremely vital manner. The world's leading medical trade fair and the international No. 1 for the medical technology supply sector once again impressively underscored their positive results from the previous year with strong numbers – despite continuing adverse conditions. A significant increase in bookings on the part of the exhibiting companies was followed after four days by a marked increase…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/medica-und-compamed-praesentieren-sich-als-aeusserst-vitale-plattformen-bewegten-zeiten
  • Viral cancer therapy - 26/10/2022 Microscopic image of plaque formation by HSV1 viruses (green fluorescing).

    Therapeutic viruses against tumours and metastases

    Viruses can overcome cell barriers and transfer information to their host cells. They know how to make their host cell’s infrastructure work for them. This makes them excellent biotechnological tools, which a research group from the Fraunhofer IGB in Stuttgart is using to its advantage. The team is developing a therapeutic virus that not only recognises and fights tumours, but also has the potential to reach metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapeutic-viruses-against-tumours-and-metastases

Page 1 / 4

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search